Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidylarginine deiminase 1 (PADI1) is an enzyme that catalyzes the conversion of arginine residues in proteins to citrulline residues, a process known as deimination or citrullination. It plays a crucial role in skin physiology, particularly in epidermal differentiation and maintaining the cutaneous barrier function. Dysregulation of PADI1 is implicated in various autoimmune diseases and cancers, making it a potential therapeutic target.
Pharmacological inhibition of PADI1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidylarginine deiminase 1 (PADI1).